KYNTRA BIO, INC. Stockholders Equity

• KYNTRA BIO, INC. showed an increase of +86.7% in Stockholders Equity from 2024 to 2025.
• This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $184.62 million | Q2 2015: $253.62 million | Q3 2015: $217.28 million | Q1 2016: $156.95 million | Q2 2016: $193.11 million | Q3 2016: $178.35 million | Q1 2017: $131.70 million | Q2 2017: $230.10 million | Q3 2017: $571.50 million | Q1 2018: $499.52 million | Q2 2018: $495.53 million | Q3 2018: $471.31 million | Q1 2019: $489.22 million | Q2 2019: $629.03 million | Q3 2019: $594.45 million | Q1 2020: $458.36 million | Q2 2020: $395.87 million | Q3 2020: $451.66 million | Q1 2021: $371.00 million | Q2 2021: $260.58 million | Q3 2021: $325.79 million | Q1 2022: $158.05 million | Q2 2022: $103.78 million | Q3 2022: $26.31 million | Q1 2023: -$48.85 million | Q2 2023: -$102.27 million | Q3 2023: -$157.17 million | Q1 2024: -$228.12 million | Q2 2024: -$232.34 million | Q3 2024: -$243.67 million | Q1 2025: -$216.90 million | Q2 2025: -$223.00 million | Q3 2025: -$17.03 million.
• Over the full 12 years of available data (2014 to 2025), KYNTRA BIO, INC.'s Stockholders Equity has declined by 113.6%.
• Historical annual values: Fiscal year 2025: -$30.04 million | Fiscal year 2024: -$225.60 million | Fiscal year 2023: -$204.17 million | Fiscal year 2022: -$21.45 million | Fiscal year 2021: $209.15 million | Fiscal year 2020: $422.18 million | Fiscal year 2019: $516.14 million | Fiscal year 2018: $509.20 million | Fiscal year 2017: $528.47 million | Fiscal year 2016: $155.84 million | Fiscal year 2015: $177.55 million | Fiscal year 2014: $221.41 million.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026